 We're trying to do it, but I think that right now we haven't been successful yet in convincing the FDA and taking action to qualify a new endpoint. And the qualification of that endpoint allows us to take advantage of some of the expedited pathways that other conditions are taking advantage of with the FDA to bring new therapies more quickly onto the market.